BioSpace News Archive

Rallybio Corporation, a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, announced the pricing of its initial public offering of 6,200,000 shares of common stock at a public offering price of $13.00 per share.

Nuvalent, Inc. announced the pricing of its initial public offering of 9,750,000 shares of common stock, consisting of 9,150,000 shares of Class A common stock and 600,000 shares of Class B common stock, each at a price to the public of $17.00 per share.